MedTrace Logo

The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population

NCT05159544 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60000

Last updated 2024-04-17

No results posted yet for this study

Summary

The integrative study by Fudan and Singlera for cancer early detection(The FuSion Program ) will evaluate sensitivity,specificity and positive/negative predictive value of the screening model jointly developed by FuDan University and Singlera in a 2-year follow-up corhort including 10,000 persons in routine annual physicals from dozens of hospitals. The multi-omics model for pan-cancer screening will be developed in a 3-year follow-up corhort including 50,000 natural persons in community containing genetic information of tumor families, assessment of epidemiological risk factors, tumor markers, proteomics, genomics and DNA methylation. After optimizing, the ability of this model will be validated in the Taizhou corhort in reality.

Conditions

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Singlera Genomics Inc.

    lead INDUSTRY

Principal Investigators

  • Xingdong Chen, Ph.D · Fudan University Taizhou Institute of Health Sciences, Taizhou, China

  • Rui Liu, Ph.D · Singlera Genomics Inc.

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2024-07-06
Completion
2024-12-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159544 on ClinicalTrials.gov